Considering that pan-CDK inhibitors are frequently used in tumor treatment and that some of them have a markedly high affinity for Cdk5, indirectly regulating the stability of Drosha expression by inhibiting Cdk5 seems to be a feasible and cost-effective strategy for achieving neuroprotective effects early after TBI. This evidence concerns the gene DROSHA and neoplasm.